Can an extra HIV drug flush out the hidden virus?
NCT ID NCT07193875
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This completed Phase 4 trial tested whether adding efavirenz (a standard HIV drug) to a person's usual combination therapy could reduce the size of the hidden HIV reservoir. Seven adults with well-controlled HIV took one extra pill daily for six months. Researchers measured safety and checked for changes in the virus's hiding places in blood and tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Efavirenz 600mg
- What this could lead to
- If it works, this could point toward a way to reduce the hidden HIV reservoir, potentially making it easier to control the virus long-term.
- What could go wrong
- This is a very small, early-phase trial with only 7 participants, so results may not apply broadly. Efavirenz can cause side effects like mood changes or rash.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University in St Louis
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peer support may lift the cloud of loneliness for older gay men with HIV
- Can peer mentors help gay men with HIV stay in care?
- HIV and hidden health risks: a major study probes the link
- Faith-Based therapy aims to heal trauma in young women
- Bringing HIV care to the community: a new test in zambia
- Could intense workouts reverse cognitive decline in older HIV patients?